yahoo_financeOriginal article
Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)
RegulatoryApitegromabNeutral
AI Analysis
Summary
Scholar Rock provided an update on the timing of the CHMP opinion for apitegromab's Marketing Authorisation Application for spinal muscular atrophy, though specific dates and details are not disclosed in this announcement.
Outcome Details
CHMP opinion timing update for Marketing Authorisation Application
Importance:5/10
Sentiment:
0.00
regulatoryEuropeCHMPMAASMA
Related Companies
Read the original article
Published by yahoo_finance on July 20, 2026 12:00 PM